Cholangiocarcinoma

Cholangiocarcinoma is a malignant neoplasm arising from the epithelial cells of the intrahepatic or extrahepatic bile ducts. In veterinary medicine, it is the second most common primary hepatic tumor in dogs and the most common primary hepatic tumor in cats. The tumor can be classified as intrahepatic (arising within the liver parenchyma) or extrahepatic (arising from the extrahepatic bile ducts, including the common bile duct and gallbladder). Intrahepatic cholangiocarcinomas are more common in dogs, while extrahepatic forms are more frequently reported in cats. The tumor is characterized by aggressive local invasion, early metastasis to regional lymph nodes, lungs, and other abdominal organs, and a generally poor prognosis. Grossly, the tumor may appear as a solitary mass, multiple nodules, or a diffuse infiltrative process. Histologically, it is composed of tubular, acinar, or papillary structures lined by cuboidal to columnar epithelial cells with varying degrees of atypia and desmoplasia. The tumor can be associated with chronic biliary inflammation, parasitic infections (e.g., Opisthorchis viverrini in endemic areas), and exposure to chemical carcinogens, although in most veterinary cases the etiology is unknown.

The exact etiology of cholangiocarcinoma in dogs and cats is largely unknown, but several risk factors have been identified. Chronic inflammation of the biliary tract, such as that caused by cholangitis, cholangiohepatitis, or biliary calculi, is considered a predisposing factor. In humans, infection with liver flukes (Opisthorchis viverrini, Clonorchis sinensis) is a well-established cause, and similar parasitic infections have been reported in endemic regions, though they are rare in North America and Europe. Exposure to chemical carcinogens, including nitrosamines, aflatoxins, and thorium dioxide (Thorotrast), has been implicated in human cases, but such exposures are uncommon in companion animals. Genetic mutations, such as alterations in KRAS, TP53, and SMAD4, have been identified in human cholangiocarcinoma and may play a role in veterinary cases, but specific genetic studies in dogs and cats are limited. Chronic hepatitis and cirrhosis have been associated with intrahepatic cholangiocarcinoma in humans, and similar chronic liver disease may predispose animals. Additionally, there is a reported association with inflammatory bowel disease and primary sclerosing cholangitis in humans, but these associations are not well-documented in veterinary patients. In cats, cholangiocarcinoma has been linked to chronic cholangitis, particularly lymphocytic cholangitis, which is a common inflammatory liver disease in cats. Overall, the development of cholangiocarcinoma is likely multifactorial, involving a combination of genetic predisposition, chronic inflammation, and environmental exposures.

Cholangiocarcinoma is a relatively uncommon tumor in dogs and cats, accounting for approximately 1-2% of all canine neoplasms and 0.6-1.5% of feline neoplasms. Among primary hepatic tumors, it is the second most common in dogs (after hepatocellular carcinoma) and the most common in cats. The tumor typically affects middle-aged to older animals, with a median age of 10-12 years in dogs and 10-12 years in cats. There is no strong sex predilection, though some studies suggest a slight male predominance in dogs. Certain breeds may be at increased risk, including Labrador Retrievers, Golden Retrievers, and German Shepherds in dogs, and Siamese and Domestic Shorthair cats in cats, but these breed associations are not consistently reported. Geographic variation exists, with higher incidence in regions where liver fluke infections are endemic, such as Southeast Asia, but in North America and Europe, the disease is sporadic. No clear seasonal pattern has been identified. The tumor is more commonly diagnosed in older animals, and the incidence may be increasing due to improved diagnostic imaging and increased longevity of pets.

Cholangiocarcinoma arises from the epithelial cells lining the bile ducts. The pathogenesis involves a stepwise progression from chronic inflammation and hyperplasia to dysplasia and ultimately malignant transformation. Chronic inflammation leads to the production of reactive oxygen species and cytokines, which can cause DNA damage and promote cellular proliferation. Mutations in oncogenes and tumor suppressor genes, such as KRAS, TP53, and SMAD4, disrupt normal cell cycle regulation and apoptosis, leading to uncontrolled growth. The tumor cells invade the surrounding hepatic parenchyma and bile duct walls, often eliciting a desmoplastic response characterized by abundant fibrous stroma. This desmoplasia contributes to the firm, white, scirrhous appearance of the tumor on gross examination. As the tumor grows, it can obstruct bile ducts, leading to cholestasis, jaundice, and secondary biliary cirrhosis. Vascular invasion is common, with tumor cells gaining access to portal and hepatic veins, resulting in intrahepatic metastasis and dissemination to distant sites, particularly the lungs, regional lymph nodes, and peritoneum. The tumor also induces angiogenesis, promoting its own blood supply. Systemically, the tumor can cause paraneoplastic syndromes, including hypoglycemia, leukocytosis, and hypercalcemia, though these are rare. The aggressive local invasion and early metastasis contribute to the poor prognosis associated with this neoplasm.

Several factors may predispose dogs and cats to the development of cholangiocarcinoma. Chronic inflammatory conditions of the biliary tract, such as cholangitis, cholangiohepatitis, and cholecystitis, are significant risk factors, particularly in cats with lymphocytic cholangitis. Biliary calculi (gallstones) and bile duct obstruction can cause chronic irritation and inflammation, increasing the risk of malignant transformation. Parasitic infections, especially liver flukes (Opisthorchis viverrini, Clonorchis sinensis), are a major risk factor in endemic areas, though they are rare in North America and Europe. Exposure to environmental carcinogens, such as aflatoxins (found in moldy grains) and nitrosamines (found in processed meats), may contribute to the development of the tumor. Genetic predisposition is suggested by breed associations, though specific genetic markers have not been identified. Age is a significant risk factor, with the tumor occurring more frequently in older animals. Immunosuppression, whether due to concurrent disease or immunosuppressive therapy, may also increase susceptibility. Additionally, obesity and diabetes mellitus have been associated with an increased risk of cholangiocarcinoma in humans, and similar metabolic factors may play a role in veterinary patients, though evidence is limited.

Clinical signs of cholangiocarcinoma are often nonspecific and may be absent in early stages. As the tumor progresses, common signs include lethargy, anorexia, weight loss, vomiting, and diarrhea. Jaundice (icterus) is a prominent feature, especially in extrahepatic cholangiocarcinoma, due to bile duct obstruction. Abdominal distension may occur due to hepatomegaly, ascites, or a palpable abdominal mass. Polyuria and polydipsia can be seen secondary to hepatic dysfunction or paraneoplastic hypercalcemia. In some cases, signs of hypoglycemia, such as weakness, tremors, or seizures, may occur. Fever may be present if there is secondary bacterial cholangitis. On physical examination, hepatomegaly, a cranial abdominal mass, and icterus are common findings. Ascites may be detected on abdominal palpation or ballottement. In advanced cases, signs of respiratory distress may develop due to pulmonary metastasis. The clinical course can be acute or chronic, with some animals presenting with acute onset of jaundice and others with a gradual decline over weeks to months. The severity of clinical signs often correlates with the extent of tumor burden and the degree of biliary obstruction.

The differential diagnoses for cholangiocarcinoma include other primary hepatic tumors, metastatic neoplasia, and non-neoplastic hepatic diseases. Key differentials include: 1) Hepatocellular carcinoma: This is the most common primary hepatic tumor in dogs and can present as a solitary mass. It is often associated with elevated liver enzymes, but jaundice is less common unless there is bile duct compression. Histopathology is definitive, with hepatocellular origin. 2) Hepatic adenoma: A benign tumor that may be indistinguishable on imaging but has a better prognosis. Histopathology shows well-differentiated hepatocytes without invasion. 3) Metastatic neoplasia: Tumors from the spleen, pancreas, gastrointestinal tract, or mammary glands can metastasize to the liver. A thorough search for a primary tumor is necessary. 4) Biliary cystadenoma: A benign cystic tumor of the bile ducts, which can be differentiated by imaging (well-defined cysts) and histopathology. 5) Cholangitis/cholangiohepatitis: Inflammatory disease of the bile ducts, which can cause similar clinical signs and imaging changes. Liver biopsy is essential for differentiation. 6) Hepatic abscess: A focal infection that can mimic a mass lesion. Ultrasound-guided aspiration and culture can differentiate. 7) Nodular hyperplasia: Common in older dogs, presenting as multiple nodules. Histopathology shows benign hepatocyte proliferation. 8) Hepatic lymphoma: Diffuse infiltration of the liver by neoplastic lymphocytes, often associated with peripheral lymphadenopathy and cytopenias. Cytology or biopsy is diagnostic. 9) Gallbladder mucocele: A sterile accumulation of mucus in the gallbladder, which can cause biliary obstruction and jaundice. Ultrasound shows a characteristic stellate pattern. 10) Cirrhosis: Chronic liver disease with fibrosis and nodular regeneration, which can mimic a mass on imaging. Liver biopsy is needed for definitive diagnosis.

The diagnostic approach to a suspected cholangiocarcinoma should be systematic and stepwise. 1) Initial evaluation: A thorough history and physical examination, with particular attention to signs of hepatic disease (jaundice, hepatomegaly, ascites). 2) Baseline bloodwork: Complete blood count (CBC), serum biochemistry profile, and urinalysis. These may reveal elevated liver enzymes (ALP, ALT, GGT), hyperbilirubinemia, hypoalbuminemia, and prolonged clotting times. 3) Abdominal ultrasound: This is the imaging modality of choice for initial assessment. It can identify a hepatic mass, biliary obstruction, and extrahepatic disease. Ultrasound-guided fine-needle aspiration (FNA) or biopsy can be performed for cytologic or histopathologic diagnosis. 4) Advanced imaging: Computed tomography (CT) or magnetic resonance imaging (MRI) may be recommended for surgical planning, as they provide better characterization of the tumor extent, vascular invasion, and metastasis. 5) Thoracic radiographs: To evaluate for pulmonary metastasis. 6) Histopathology: Definitive diagnosis requires histopathologic examination of a biopsy sample. This can be obtained via ultrasound-guided core biopsy, laparoscopic biopsy, or surgical biopsy. 7) Staging: If cholangiocarcinoma is confirmed, staging should include assessment of regional lymph nodes (via ultrasound or CT) and abdominal cavity for carcinomatosis. 8) Additional tests: In cases with suspected paraneoplastic syndromes, serum glucose, calcium, and insulin levels may be measured. 9) Genetic testing: Not routinely performed in veterinary medicine, but may be considered in research settings.

Laboratory abnormalities in cholangiocarcinoma are often consistent with cholestasis and hepatocellular damage. On CBC, there may be a mild to moderate leukocytosis due to inflammation or paraneoplastic neutrophilia. Anemia may be present due to chronic disease or blood loss. Serum biochemistry typically shows elevated alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) activities, reflecting cholestasis. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) may be elevated due to hepatocellular injury. Hyperbilirubinemia (total and direct) is common, especially in extrahepatic obstruction. Hypoalbuminemia may occur due to decreased hepatic synthesis. Blood urea nitrogen (BUN) may be decreased due to impaired hepatic urea cycle. Electrolyte abnormalities, such as hyponatremia and hypokalemia, can occur secondary to vomiting or diuretic therapy. Coagulation abnormalities, including prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), may be present due to decreased synthesis of clotting factors. Urinalysis may reveal bilirubinuria, which is abnormal in dogs (cats can have small amounts). Specific biomarkers such as serum bile acids may be elevated, indicating hepatobiliary dysfunction. In cases of paraneoplastic hypoglycemia, serum glucose will be low. Hypercalcemia may be present in some cases. Cytologic examination of ascitic fluid, if present, may reveal neoplastic cells, though this is uncommon.

Imaging plays a crucial role in the diagnosis and staging of cholangiocarcinoma. Abdominal radiography may show hepatomegaly, a soft tissue mass in the cranial abdomen, or loss of abdominal detail due to ascites. However, radiography is insensitive for detecting hepatic masses. Abdominal ultrasonography is the primary imaging modality. Findings may include a solitary hypoechoic or mixed echogenic mass, multiple nodules, or a diffuse infiltrative pattern. The mass may have irregular borders and may be associated with biliary dilation. Extrahepatic cholangiocarcinoma may cause obstruction of the common bile duct, leading to dilation of the intrahepatic bile ducts and gallbladder. Doppler ultrasound can assess vascular invasion. Ultrasound-guided fine-needle aspiration or biopsy can be performed for cytologic or histopathologic diagnosis. Computed tomography (CT) provides superior contrast resolution and allows for three-dimensional assessment of the tumor, vascular involvement, and metastasis. CT angiography can identify arterial and venous invasion. Magnetic resonance imaging (MRI) offers excellent soft tissue contrast and is particularly useful for evaluating the biliary tree. Magnetic resonance cholangiopancreatography (MRCP) can delineate the biliary anatomy. Thoracic radiographs or CT are essential to rule out pulmonary metastasis. In some cases, endoscopic retrograde cholangiopancreatography (ERCP) may be used to visualize the extrahepatic bile ducts, but this is rarely performed in veterinary medicine.

Cytologic examination of fine-needle aspirates from a hepatic mass can provide a presumptive diagnosis of cholangiocarcinoma. The aspirate may contain clusters of epithelial cells with moderate to marked anisocytosis, anisokaryosis, and prominent nucleoli. The cells may form acinar or tubular structures. However, cytology has limited sensitivity and specificity, and a definitive diagnosis requires histopathology. Histopathologic examination of a biopsy sample is the gold standard. The tumor is characterized by infiltrative growth of tubular, acinar, or papillary structures lined by cuboidal to columnar epithelial cells. The cells exhibit variable degrees of atypia, including nuclear pleomorphism, hyperchromasia, and increased mitotic activity. Desmoplasia (fibrous stroma) is a common feature. The tumor may invade the surrounding hepatic parenchyma, blood vessels, and lymphatic vessels. Special stains, such as cytokeratin 7 (CK7) and cytokeratin 19 (CK19), are positive in cholangiocarcinoma, helping to differentiate it from hepatocellular carcinoma (which is CK8/18 positive). Mucicarmine stain may highlight intracytoplasmic mucin. Immunohistochemistry for markers such as carcinoembryonic antigen (CEA) and CA19-9 may be supportive but are not routinely used in veterinary medicine. Histopathologic grading (well, moderately, poorly differentiated) may have prognostic significance, with poorly differentiated tumors having a worse prognosis.

Treatment of cholangiocarcinoma depends on the extent of disease and the presence of metastasis. Surgical resection is the treatment of choice for solitary intrahepatic masses without evidence of metastasis. A partial hepatectomy (lobectomy) can be curative if complete margins are achieved. For extrahepatic cholangiocarcinoma involving the common bile duct, surgical resection may be more challenging, and a cholecystectomy or biliary diversion procedure may be necessary. In cases where surgery is not feasible, palliative options include chemotherapy and radiation therapy. Chemotherapy protocols for cholangiocarcinoma are not well-established in veterinary medicine, but drugs such as doxorubicin, mitoxantrone, carboplatin, and gemcitabine have been used with variable responses. A commonly used protocol is doxorubicin (30 mg/m² IV every 3 weeks) or gemcitabine (800-1000 mg/m² IV every 3 weeks). Metronomic chemotherapy with cyclophosphamide (10 mg/m² PO every 24 hours) and piroxicam (0.3 mg/kg PO every 24 hours) may be considered for its anti-angiogenic and immunomodulatory effects. Radiation therapy can be used for local control, particularly for non-resectable tumors, but its efficacy is limited. Supportive care is essential and includes fluid therapy, antiemetics (e.g., maropitant 1 mg/kg IV or PO every 24 hours), hepatoprotectants (e.g., S-adenosylmethionine 20 mg/kg PO every 24 hours, ursodeoxycholic acid 10-15 mg/kg PO every 24 hours), and nutritional support. In cases of biliary obstruction, placement of a biliary stent may be considered, though this is technically challenging in veterinary patients. Pain management with opioids (e.g., buprenorphine 0.01-0.02 mg/kg IV or IM every 6-8 hours) may be necessary. The prognosis is generally poor, with median survival times of 1-6 months without treatment and up to 12 months with aggressive surgical resection.

The prognosis for cholangiocarcinoma is generally poor due to its aggressive nature and high metastatic potential. Without treatment, median survival times are typically 1-3 months. With surgical resection of a solitary intrahepatic mass, median survival times can be extended to 6-12 months, but recurrence is common. Factors associated with a worse prognosis include: presence of metastasis at diagnosis, extrahepatic location, poorly differentiated histology, high mitotic index, vascular invasion, and incomplete surgical margins. Cats may have a slightly better prognosis than dogs, but overall survival is still limited. Negative prognostic biomarkers include elevated serum bilirubin, hypoalbuminemia, and elevated ALP. Response to chemotherapy is variable, and most tumors are considered chemoresistant. The presence of paraneoplastic syndromes, such as hypoglycemia, may also indicate a poorer prognosis. Long-term survival (>2 years) is rare but has been reported in a few cases with early detection and complete surgical excision. Regular monitoring is essential to detect recurrence or metastasis early.

After diagnosis and treatment, regular follow-up is essential to monitor for recurrence and metastasis. For the first 3 months, re-evaluations should be performed every 2-4 weeks, including physical examination, CBC, serum biochemistry, and abdominal ultrasound. After 3 months, if the patient is stable, re-checks can be spaced to every 1-3 months. Thoracic radiographs should be repeated every 1-3 months to screen for pulmonary metastasis. If the patient is receiving chemotherapy, bloodwork should be performed before each dose to assess for myelosuppression and hepatotoxicity. Dose adjustments may be necessary based on hematologic and biochemical parameters. For patients on metronomic chemotherapy, monitoring for gastrointestinal toxicity and renal function is recommended. Nutritional status should be assessed regularly, and dietary adjustments may be needed to support hepatic function. Owners should be educated on signs of tumor progression, such as lethargy, anorexia, vomiting, jaundice, or abdominal distension, and advised to seek immediate veterinary attention if these occur. In cases of surgical resection, repeat imaging (ultrasound or CT) is recommended at 3, 6, and 12 months post-operatively, then annually. Long-term management may include hepatoprotectants and a liver-supportive diet. The overall goal is to maintain quality of life and delay disease progression.

Pearls: 1) Cholangiocarcinoma should be considered in any older dog or cat with a hepatic mass and jaundice. 2) Ultrasound-guided FNA can provide a rapid presumptive diagnosis, but a core biopsy is needed for definitive histopathology. 3) Surgical resection offers the best chance for long-term survival if the tumor is solitary and no metastasis is present. 4) Preoperative staging with CT and thoracic radiographs is essential to avoid unnecessary surgery. 5) Supportive care, including hepatoprotectants and antiemetics, can improve quality of life. 6) In cats, chronic cholangitis is a risk factor, so early treatment of inflammatory liver disease may reduce the risk of malignant transformation. Pitfalls: 1) Assuming that a hepatic mass is benign without biopsy. 2) Performing surgery without adequate staging, leading to incomplete resection. 3) Overlooking extrahepatic biliary obstruction, which may require urgent intervention. 4) Using cytology alone for diagnosis, which can be misleading. 5) Failing to monitor for metastasis during follow-up. 6) Underestimating the aggressive nature of the tumor and delaying treatment. 7) Not considering paraneoplastic syndromes, such as hypoglycemia, which can cause severe clinical signs.

Chemotherapy protocols for cholangiocarcinoma are not standardized, but the following drugs have been used based on human and veterinary literature. Doxorubicin: 30 mg/m² IV every 3 weeks, with a maximum cumulative dose of 180-240 mg/m² to avoid cardiotoxicity. Monitor for myelosuppression and gastrointestinal toxicity. Mitoxantrone: 5-6 mg/m² IV every 3 weeks, less cardiotoxic than doxorubicin. Carboplatin: 300 mg/m² IV every 3 weeks, may be used in combination with other agents. Gemcitabine: 800-1000 mg/m² IV every 3 weeks, often used in combination with other drugs. Metronomic chemotherapy: Cyclophosphamide 10 mg/m² PO every 24 hours, and piroxicam 0.3 mg/kg PO every 24 hours. This protocol is well-tolerated and may have anti-angiogenic effects. Supportive medications: Maropitant (Cerenia) 1 mg/kg IV or PO every 24 hours for nausea and vomiting. Ondansetron 0.5-1 mg/kg IV or PO every 8-12 hours as an alternative. S-adenosylmethionine (SAMe) 20 mg/kg PO every 24 hours for hepatic support. Ursodeoxycholic acid 10-15 mg/kg PO every 24 hours to improve bile flow. Vitamin K1 0.5-1.5 mg/kg SC or IM every 12 hours if coagulopathy is present. Pain management: Buprenorphine 0.01-0.02 mg/kg IV or IM every 6-8 hours, or tramadol 2-5 mg/kg PO every 8-12 hours. Antibiotics: If secondary cholangitis is suspected, amoxicillin-clavulanate 12.5-25 mg/kg PO every 12 hours, or enrofloxacin 5-10 mg/kg PO or IV every 24 hours. All dosages should be adjusted based on renal and hepatic function, and patients should be monitored closely for adverse effects.

Evidence for the management of cholangiocarcinoma in dogs and cats is limited to retrospective studies and case reports. A retrospective study by Patnaik et al. (1981) described the clinical and pathologic features of cholangiocarcinoma in dogs and cats, noting a poor prognosis. Another study by Liptak et al. (2004) evaluated surgical outcomes in dogs with liver tumors, including cholangiocarcinoma, and found that complete resection was associated with longer survival. A more recent study by van Sprundel et al. (2014) reviewed the histopathologic features and clinical outcomes of feline cholangiocarcinoma, reporting a median survival of 6 months with treatment. Chemotherapy data are sparse, but a study by Batschinski et al. (2014) reported on the use of gemcitabine in dogs with various tumors, including cholangiocarcinoma, showing some responses. Metronomic chemotherapy has been evaluated in a study by Elmslie et al. (2008) for canine tumors, but specific data for cholangiocarcinoma are lacking. Consensus guidelines from the World Small Animal Veterinary Association (WSAVA) and the American College of Veterinary Internal Medicine (ACVIM) recommend a multimodal approach, but evidence-based recommendations are limited. Overall, the literature supports surgical resection as the primary treatment, with chemotherapy reserved for non-resectable or metastatic disease. Further prospective studies are needed to establish optimal chemotherapy protocols and prognostic factors.